The present invention relates to a delayed release composition comprising enteric coated drug loaded in psyllium husk matrix. The invention specifically provides curcumin loaded in psyllium husk matrix with 25% ethanol solvent used for the preparation of composition which is coated with enteric polymer like hydroxypropyl methyl cellulose.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.

The present invention relates to a composition based on components of natural origin, in particular ozonized olive oil and liquid vegetable extracts, for the topical treatment of vaginosis and/or vulvovaginitis of bacterial and/or fungal origin.

The present invention relates to a composition based on components of natural origin, in particular ozonized olive oil and liquid vegetable extracts, for the topical treatment of vaginosis and/or vulvovaginitis of bacterial and/or fungal origin.

The present invention relates to a composition based on components of natural origin, in particular ozonized olive oil and liquid vegetable extracts, for the topical treatment of vaginosis and/or vulvovaginitis of bacterial and/or fungal origin.

The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.

The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.

Disclosed are compositions and methods for the treatment of a disease or disorder comprising i) at least one fatty acid, and ii) at least one cholesterol lowering compound. Compositions and methods of the disclosure reduce total cholesterol and maintain total cholesterol homeostasis.